Integrin Targeted Therapeutics

被引：202

作者：

Millard, Melissa ^{[1
]}

Odde, Srinivas ^{[1
]}

Neamati, Nouri ^{[1
]}

机构：

[1] Univ So Calif, Sch Pharm, Dept Pharmacol & Pharmaceut Sci, Los Angeles, CA 90089 USA

来源：

THERANOSTICS | 2011年 / 1卷

基金：

美国国家卫生研究院;

关键词：

Integrin-targeted therapeutics; abciximab; tirofiban; eptifibatide; natalizumab; cilengitide; abegrin; acute coronary syndromes; Multiple Sclerosis; Crohn's Disease; cancer; angiogenesis; osteoporosis; age related macular degeneration; integrin-targeted small molecules; integrin-targeted peptides; integrin-targeted therapeutic antibodies; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; ADVANCED SOLID TUMORS; PERCUTANEOUS CORONARY INTERVENTION; GLYCOPROTEIN IIB/IIIA ANTAGONISTS; INDUCED AIRWAY RESPONSES; INHIBITOR CILENGITIDE EMD-121974; HUMANIZED MONOCLONAL-ANTIBODY; RELAPSING MULTIPLE-SCLEROSIS; CELL-ADHESION MOLECULE-1; PLACEBO-CONTROLLED TRIAL;

D O I：

10.7150/thno/v01p0154

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Integrins are heterodimeric, transmembrane receptors that function as mechanosensors, adhesion molecules and signal transduction platforms in a multitude of biological processes. As such, integrins are central to the etiology and pathology of many disease states. Therefore, pharmacological inhibition of integrins is of great interest for the treatment and prevention of disease. In the last two decades several integrin-targeted drugs have made their way into clinical use, many others are in clinical trials and still more are showing promise as they advance through preclinical development. Herein, this review examines and evaluates the various drugs and compounds targeting integrins and the disease states in which they are implicated.

引用

页码：154 / 188

页数：35

共 149 条

[1] A small-molecule, tight-binding inhibitor of the integrin α4β1 blocks antigen-induced airway responses and inflammation in experimental asthma in sheep [J].

Abraham, WM ;

Gill, A ;

Ahmed, A ;

Sielczak, MW ;

Lauredo, IT ;

Botinnikova, Y ;

Lin, KC ;

Pepinsky, B ;

Leone, DR ;

Lobb, RR ;

Adams, SP .

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2000, 162 (02) :603-611

[2] Three-dimensional model of the human platelet integrin αllbβ3 based on electron cryomicroscopy and x-ray crystallography [J].

Adair, BD ;

Yeager, M .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (22) :14059-14064

[3] Integrin αVβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models [J].

Albert, Jeffrey M. ;

Cao, Carolyn ;

Ling Geng ;

Leavitt, Lauren ;

Hallahan, Dennis E. ;

Bo Lu .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 65 (05) :1536-1543

[4] Recent antiplatelet drug trials in the acute coronary syndromes - Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT [J].

Alexander, JH ;

Harrington, RA .

DRUGS, 1998, 56 (06) :965-976

[5] Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis [J].

Anand, SS ;

Yusuf, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2058-2067

[6]

Anthony Fauci.S., 2008, HARRISONS PRINCIPLES

[7] Integrins in angiogenesis and lymphangiogenesis [J].

Avraamides, Christie J. ;

Garmy-Susini, Barbara ;

Varner, Judith A. .

NATURE REVIEWS CANCER, 2008, 8 (08) :604-617

[8] A mechanistic model for paradoxical platelet activation by ligand-mimetic αIIbβ3 (GPIIb/IIIa) antagonists [J].

Bassler, Nicole ;

Loeffler, Christoph ;

Mangin, Pierre ;

Yuan, Yuping ;

Schwarz, Meike ;

Hagemeyer, Christoph E. ;

Eisenhardt, Steffen U. ;

Ahrens, Ingo ;

Bode, Christoph ;

Jackson, Shaun P. ;

Peter, Karlheinz .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (03) :E9-E15

[9]

Bayless KJ, 1998, J CELL SCI, V111, P1165

[10]

Berkowitz SD, 1997, CIRCULATION, V95, P809

← 1 2 3 4 5 6 7 8 9 10 →